Becton Dickinson (MEX:BDX) ROCE % : 5.70% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Becton Dickinson ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Becton Dickinson's annualized ROCE % for the quarter that ended in Sep. 2024 was 5.70%.

Becton Dickinson ROCE % Historical Data

The historical data trend for Becton Dickinson's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Becton Dickinson ROCE % Chart

Becton Dickinson Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

ROCE %

Get a 7-Day Free Trial

2.11

4.37

4.67

4.30

5.68

Becton Dickinson Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															2.57	4.08	6.55	5.58	5.70

Becton Dickinson ROCE % Calculation

Becton Dickinson's annualized ROCE % for the fiscal year that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	49875.53	/	( ( (919369.384 - 115678.895)	+	(1127978.527 - 176346.327) )	/ 2 )
	=	49875.53	/	( (803690.489	+	951632.2)	/ 2 )
	=	49875.53	/	877661.3445
	=	5.68 %

Becton Dickinson's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	52691.244	/	( ( (1018267.966 - 121004.28)	+	(1127978.527 - 176346.327) )	/ 2 )
	=	52691.244	/	( ( 897263.686	+	951632.2 )	/ 2 )
	=	52691.244	/	924447.943
	=	5.70 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Becton Dickinson (MEX:BDX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Becton Dickinson ROCE % Related Terms

Thank you for viewing the detailed overview of Becton Dickinson's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Becton Dickinson Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Becton Dickinson & Co (MEX:BDX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BDX:USA 1BDX:Italy 0R19:UK BOX:Germany BOX:Germany BOX:Germany BDX:Austria

Address

1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880

Website

https://www.bd.com

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.